v3.25.1

Operating costs and other operating income (Tables)

12 Months Ended

Dec. 31, 2024

Operating costs and other operating income

Summary of research and development expenditure

​

​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​		2024			2023			2022
​	​	​	(Euro, in thousands)
Personnel costs	​	€	(87,740)	​	€	(95,788)	​	€	(115,484)
Subcontracting	​	​	(160,076)	​	​	(82,997)	​	​	(61,192)
Disposables and lab fees and premises costs	​	​	(17,629)	​	​	(18,083)	​	​	(19,529)
Depreciation, amortization and impairment	​	​	(35,378)	​	​	(22,254)	​	​	(51,493)
Professional fees	​	​	(15,949)	​	​	(9,272)	​	​	(9,316)
Other operating expenses	​	​	(18,687)	​	​	(12,900)	​	​	(12,783)
Total R&D expenses	​	€	(335,459)	​	€	(241,294)	​	€	(269,797)

Summary of R&D expenditure by program

​

​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​		2024			2023			2022
​	​	​	(Euro, in thousands)
​	​	​	​	​	​	​	​	​	​
Ziritaxestat program	​	€	—	​	€	—	​	€	(1,096)
SIKi program	​	​	(18,400)	​	​	(18,900)	​	​	(47,727)
TYK2 program on GLPG3667	​	​	(34,965)	​	​	(31,289)	​	​	(24,467)
Cell therapy programs in oncology	​	​	(170,998)	​	​	(82,218)	​	​	(29,999)
Other discovery programs	​	​	(111,096)	​	​	(108,887)	​	​	(166,507)
Total R&D expenses	​	€	(335,459)	​	€	(241,294)	​	€	(269,797)

Summary of sales and marketing expenses

​

​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​		2024			2023			2022
​	​	​	(Euro, in thousands)
Personnel costs	​	€	(6,561)	​	€	(2,997)	​	€	(1,693)
Depreciation and impairment	​	​	(4,475)	​	​	(113)	​	​	(59)
External outsourcing costs	​	​	(2,813)	​	​	(1,776)	​	​	(1,267)
Professional fees	​	​	(904)	​	​	(131)	​	​	(99)
Other operating expenses	​	​	(2,440)	​	​	(659)	​	​	(363)
Total sales and marketing expenses	​	€	(17,193)	​	€	(5,676)	​	€	(3,480)

Summary of general and administrative expenses

​

​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​		2024			2023			2022
​	​	​	(Euro, in thousands)
Personnel costs	​	€	(52,642)	​	€	(66,098)	​	€	(76,536)
Depreciation and impairment	​	​	(8,697)	​	​	(15,978)	​	​	(8,529)
Legal and professional fees	​	​	(33,960)	​	​	(23,250)	​	​	(23,715)
Other operating expenses	​	​	(21,946)	​	​	(22,963)	​	​	(26,375)
Total general and administrative expenses	​	€	(117,245)	​	€	(128,289)	​	€	(135,155)

Schedule of other income

​

​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​		2024			2023			2022
​	​	​	(Euro, in thousands)
Grant income	​	€	2,035	​	€	6,618	​	€	1,873
R&D incentives income	​	​	27,223	​	​	32,968	​	​	29,104
Other income	​	​	11,515	​	​	7,686	​	​	5,150
Total other operating income	​	€	40,773	​	€	47,272	​	€	36,127

Schedule of R&D incentives income

​

​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​		2024			2023			2022
​	​	​	(Euro, in thousands)
Income from innovation incentive system in France	​	€	2,056	​	€	5,881	​	€	11,075
Income from Belgian R&D incentives	​	​	16,943	​	​	16,535	​	​	10,339
Tax rebates on payroll withholding taxes of R&D personnel (Belgium & the Netherlands)	​	​	8,224	​	​	10,552	​	​	7,689
Total R&D incentives income	​	€	27,223	​	€	32,968	​	€	29,104

​

X

- Definition

The disclosure of R&D Incentive Income

+ References

No definition available.

+ Details

Name:	glpg_DisclosureOfRDIncentivesIncome
Namespace Prefix:	glpg_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of research and development expenditure by individual program.

+ References

No definition available.

+ Details

Name:	glpg_DisclosureOfResearchAndDevelopmentExpenditureByProgram
Namespace Prefix:	glpg_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of sales and marketing expenses.

+ References

No definition available.

+ Details

Name:	glpg_DisclosureOfSalesAndMarketingExpensesTableTextBlock
Namespace Prefix:	glpg_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	glpg_OperatingCostsAndOtherOperatingIncomeAbstract
Namespace Prefix:	glpg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of general and administrative expenses. [Refer: Administrative expenses]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of other operating income. [Refer: Other operating income (expense)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of research and development expense. [Refer: Research and development expense]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration